Agile Therapeutics (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. New Jersey-based Agile is focused on seeking FDA approval of its lead drug Twirla, and is looking forward to its Feb 16 PDUFA date
Agile Therapeutics looks forward to Feb 16 PDUFA date
Quick facts: Agile Therapeutics
Price: 2.65 USD
Market Cap: $231.12 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE